Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes

BIOLOGICAL3 trials

Sponsors

Fred Hutchinson Cancer Center, M.D. Anderson Cancer Center, Sumithira Vasu

Conditions

AdenovirusAllogeneic Hematopoietic Stem Cell Transplantation RecipientCytomegaloviral InfectionCytomegalovirusDonorHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia

Early Phase 1

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

RecruitingNCT03665675

Sumithira VasuAdenovirus, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus +2

Start: 2020-11-07End: 2026-12-20Target: 20Updated: 2026-04-15

Phase 1

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

CompletedNCT01475058

Fred Hutchinson Cancer CenterPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia +4

Start: 2012-04-30End: 2014-07-31Updated: 2017-02-15

Phase 2

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

Active, not recruitingNCT02210078

M.D. Anderson Cancer CenterCytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

Start: 2015-02-19End: 2027-08-31Updated: 2026-08-18